MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 05-23-2026
Invitae Corporation Retained Earnings 2011-2026 | NVTA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.83 B | -1.72 B | -1.36 B | -759 M | -517 M | -399 M | -275 M | -175 M | -85.2 M | -37.7 M | -12.8 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -12.8 M | -4.83 B | -925 M |
Quarterly Retained Earnings Invitae Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.17 B | -5.23 B | -5.02 B | -4.83 B | -4.73 B | -4.43 B | -1.9 B | -1.72 B | -1.52 B | -1.32 B | -1.45 B | -1.36 B | -1.13 B | -1.02 B | -857 M | -759 M | -682 M | -603 M | -554 M | -517 M | -487 M | -455 M | -423 M | -399 M | -358 M | -331 M | -302 M | -275 M | -250 M | -225 M | -201 M | -175 M | -151 M | -128 M | -104 M | -85.2 M | -85.2 M | -85.2 M | -85.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -85.2 M | -6.17 B | -1.29 B |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 206.11 | 0.77 % | $ 22.9 B | USA |
 |
Celcuity
CELC
|
-449 M | $ 87.19 | -5.84 % | $ 4.08 B | USA |
 |
Fulgent Genetics
FLGT
|
530 M | $ 19.0 | 2.7 % | $ 585 M | USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 4.16 | -7.56 % | $ 5.53 M | USA |
 |
Castle Biosciences
CSTL
|
-224 M | $ 21.22 | 0.66 % | $ 615 M | USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-719 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Guardant Health
GH
|
-2.99 B | $ 131.65 | 1.18 % | $ 16.5 B | USA |
 |
CareDx, Inc
CDNA
|
-735 M | $ 22.89 | 0.62 % | $ 1.22 B | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
ICON Public Limited Company
ICLR
|
2.12 B | $ 150.72 | -0.73 % | $ 11.8 B |  Irlanda |
 |
Check-Cap Ltd.
CHEK
|
-166 M | - | - | $ 9.42 M |  Israel |
 |
Illumina
ILMN
|
-392 M | $ 165.92 | 3.68 % | $ 25.7 B | USA |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.79 | 2.87 % | $ 7.92 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-166 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-6.25 B | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 101.92 | 1.94 % | $ 6.88 B | USA |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 190.0 | 0.08 % | $ 9.42 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 472.58 | 1.24 % | $ 13.6 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
Mettler-Toledo International
MTD
|
9.24 B | $ 1 142.7 | -1.74 % | $ 23.6 B |  Schweiz |
 |
NeoGenomics
NEO
|
-434 M | $ 11.69 | 2.19 % | $ 1.5 B | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.61 | 1.54 % | $ 427 M | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 21.13 | 6.99 % | $ 473 M | USA |
 |
Natera
NTRA
|
-2.78 B | $ 217.87 | -2.22 % | $ 29.8 B | USA |
 |
Pacific Biosciences of California
PACB
|
-2.7 B | $ 1.39 | 1.47 % | $ 417 M | USA |
 |
Personalis
PSNL
|
-631 M | $ 10.01 | 2.62 % | $ 893 M | USA |
 |
Senseonics Holdings
SENS
|
-1.02 B | $ 7.37 | -0.81 % | $ 308 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Soleno Therapeutics
SLNO
|
-431 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.03 | -1.02 % | $ 4.66 M | USA |
 |
Twist Bioscience Corporation
TWST
|
-1.32 B | $ 68.85 | -1.73 % | $ 4.12 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 273.95 | 1.01 % | $ 22.8 B | USA |
 |
Waters Corporation
WAT
|
10.4 B | $ 369.51 | -0.44 % | $ 22 B | USA |
 |
Thermo Fisher Scientific
TMO
|
59.2 B | $ 488.1 | -1.21 % | $ 184 B | USA |
 |
Trinity Biotech plc
TRIB
|
-79.1 M | $ 0.68 | 1.91 % | $ 244 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.24 | -0.48 % | $ 2 B | USA |